Murray Yule - Concepedia

Author

Murray Yule

Dana-Farber Cancer Institute

Also Known As

M Yule, M. Yule, Murray Yule

Publications

737

Citations

H-Index

Concepts

All Affiliations

Dana-Farber Cancer Institute Harvard University BerGenBio (Norway)Massachusetts General Hospital The University of Texas MD Anderson Cancer Center

About

Murray Yule is an author at Dana-Farber Cancer Institute specializing in cell biology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	272
2	Cell Biology	5	5	289
3	Immunology	1	1	19
4	Pathology	1	1	19
5	Pharmacology	1	1	19

Murray Yule

Publications

584

Citations

H-Index

Page 1

	Year	Citations
AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition Loredana Santo, Sonia Vallet, Teru Hideshima, Oncogene Hematological MalignancyGsk-3β ActivationMedicineApoptosisCell Death	2010	141
First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors Geoffrey I. Shapiro, Eunice L. Kwak, Bruce J. Dezube, Clinical Cancer Research	2014	86
A Phase II Clinical and Pharmacodynamic Study of E7070 in Patients with Metastatic, Recurrent, or Refractory Squamous Cell Carcinoma of the Head and Neck Robert I. Haddad, Lisa J. Weinstein, Tad J. Wieczorek, Clinical Cancer Research	2004	66
A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies Hendrik‐Tobias Arkenau, Ruth Plummer, L. Rhoda Molife, Annals of Oncology MedicineReceptor Tyrosine KinaseSmall Molecule InhibitorAurora KinasesCell Biology	2011	65
A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study Lucas Moreno, Lynley V. Marshall, Andrew D.J. Pearson, Clinical Cancer Research	2014	55
A Phase I and Pharmacodynamic Study of AT9283, a Small-Molecule Inhibitor of Aurora Kinases in Patients With Relapsed/Refractory Leukemia or Myelofibrosis James M. Foran, Farhad Ravandi, William G. Wierda, Clinical Lymphoma Myeloma & Leukemia Hematological MalignancyRelapsed/refractory LeukemiaMixed-phenotype Acute LeukemiaReceptor Tyrosine KinaseAurora Kinases	2013	49
The influence of serum methotrexate concentrations and drug dosage on outcome in childhood acute lymphoblastic leukaemia A D Pearson, HA Amineddine, Murray Yule, British Journal of Cancer Hematological MalignancyTranslational MedicineDrug DosagePediatric HematologyMixed-phenotype Acute Leukemia	1991	32
Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour Andrew J. Wagner, Mark Agulnik, Michael C. Heinrich, European Journal of Cancer	2016	30
Combination of bemcentinib (BGB324): A first-in-class selective oral AXL inhibitor, with pembrolizumab in patients with triple negative breast cancer and adenocarcinoma of the lung. Murray Yule, Kjersti Davidsen, Magnus Bloe, Journal of Clinical Oncology Innate Immune SystemImmune RegulationImmunologyPathologyImmunoediting	2018	19
A Phase I/II Open-Label Multicenter Study Of The Cyclin Kinase Inhibitor AT7519M Alone and In Combination With Bortezomib In Patients With Previously Treated Multiple Myeloma Noopur Raje, Parameswaran Hari, Heather Landau, Blood	2013	16

Page 1